rutecarpine has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, XJ; Li, RT; Mu, QZ; Tan, NH; Zeng, GZ | 1 |
| Fukuma, Y; Komaki, S; Nishishita, K; Okamoto, K; Sakai, E; Tsukuba, T | 1 |
2 other study(ies) available for rutecarpine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Natural inhibitors targeting osteoclast-mediated bone resorption.
Topics: Bone Resorption; Cathepsin K; Cathepsins; Drug Design; Enzyme Inhibitors; Humans; Integrin alphaVbeta3; Matrix Metalloproteinase Inhibitors; Osteoclasts; Protease Inhibitors | 2006 |
Rutaecarpine attenuates osteoclastogenesis by impairing macrophage colony stimulating factor and receptor activator of nuclear factor κ-B ligand-stimulated signalling pathways.
Topics: Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Indole Alkaloids; Macrophage Colony-Stimulating Factor; Macrophages; Osteoclasts; Osteogenesis; Quinazolines; RANK Ligand; Signal Transduction | 2018 |